Alnylam's stock is down 30% despite a booming biotech market. Here's why.

Summary

Alnylam's stock has declined 30% in 2026 despite a recovering biotech market with increased M&A and IPO activity. The article indicates the company is viewed as a mystery in the sector without providing specific catalysts or reasons for the underperformance.